Loomis Sayles & Co. L P Sells 132,580 Shares of Illumina, Inc. (NASDAQ:ILMN)

Loomis Sayles & Co. L P decreased its holdings in Illumina, Inc. (NASDAQ:ILMN) by 3.1% in the fourth quarter, Holdings Channel reports. The firm owned 4,210,160 shares of the life sciences company’s stock after selling 132,580 shares during the period. Illumina comprises about 60.8% of Loomis Sayles & Co. L P’s portfolio, making the stock its 28th largest position. Loomis Sayles & Co. L P’s holdings in Illumina were worth $562,604,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Elo Mutual Pension Insurance Co boosted its holdings in shares of Illumina by 10.1% in the 4th quarter. Elo Mutual Pension Insurance Co now owns 15,581 shares of the life sciences company’s stock valued at $2,082,000 after acquiring an additional 1,431 shares during the last quarter. WINTON GROUP Ltd raised its position in shares of Illumina by 169.6% during the 4th quarter. WINTON GROUP Ltd now owns 38,550 shares of the life sciences company’s stock worth $5,151,000 after purchasing an additional 24,249 shares during the last quarter. Korea Investment CORP boosted its stake in Illumina by 92.9% during the 4th quarter. Korea Investment CORP now owns 70,588 shares of the life sciences company’s stock worth $9,433,000 after purchasing an additional 34,000 shares during the last quarter. Mendel Money Management purchased a new position in Illumina in the 4th quarter worth approximately $402,000. Finally, Murphy & Mullick Capital Management Corp acquired a new stake in shares of Illumina in the fourth quarter valued at approximately $61,000. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on ILMN. Royal Bank of Canada reduced their target price on shares of Illumina from $247.00 to $128.00 and set an “outperform” rating on the stock in a research note on Wednesday, March 12th. Barclays restated an “underweight” rating on shares of Illumina in a research note on Tuesday, March 11th. HSBC lowered Illumina from a “buy” rating to a “hold” rating and set a $100.00 target price on the stock. in a research report on Friday, February 28th. Hsbc Global Res cut shares of Illumina from a “strong-buy” rating to a “hold” rating in a report on Friday, February 28th. Finally, Citigroup cut their price target on Illumina from $130.00 to $90.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $140.90.

Illumina Stock Down 5.4 %

ILMN opened at $82.83 on Thursday. The stock has a market cap of $13.12 billion, a P/E ratio of -10.79, a P/E/G ratio of 1.60 and a beta of 1.17. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. The stock’s 50 day moving average price is $105.03 and its 200 day moving average price is $127.40. Illumina, Inc. has a 12 month low of $80.18 and a 12 month high of $156.66.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. As a group, research analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.